Treatment of carcinoma of the uterine cervix by remotely controlled afterloading intracavitary radiotherapy with high-dose rate: A comparative study with a low-dose rate system

Shigematsu, Y; Nishiyama, Kinji; Masaki, N; Inoue, Toshihiko; Miyata, Yoshiaki; Ikeda, Hiroshi; Ozeki, S; Kawamura, Y.; Kurachi, Keiichi

doi:10.1016/0360-3016(83)90295-x

Cited by 152 publications

(38 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patients were treated in the lithotomy position. In Japan, the method of intracavitary irradiation is based on the modified Manchester system [13] and the concept of ICRU Report 38 [14] is not in widespread use. So, doses to the ICRU bladder and rectum points were not always Cs and the radioactivity of RI was not same.…”

Section: Treatmentmentioning

confidence: 99%

Results of concomitant chemoradiation for cervical cancer using high dose rate intracavitary brachytherapy: Study of JROSG (Japan Radiation Oncology Study Group)

et al. 2008

View full text Add to dashboard Cite

Section: Treatmentmentioning

confidence: 99%

Results of concomitant chemoradiation for cervical cancer using high dose rate intracavitary brachytherapy: Study of JROSG (Japan Radiation Oncology Study Group)

et al. 2008

View full text Add to dashboard Cite

“…HDR proved to be as clinically effective as LDR in the management of cervical cancer. In rates of survival, relapse and complications, no statistically significant differences have been found between both treatment methods 2,3,4,14,15,16,17 .…”

Section: Discussionmentioning

confidence: 89%

“…Another study described late complications requiring treatment in about 11% of women undergoing HDRB. The most commonly affected site, was the rectum followed by the urinary bladder 3 . Patients who suffered from stage IIIB squamous cell carcinoma of the uterine cervix who were treated with HDRB had a better disease-free survival rate than those treated with the previously employed LDR therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Brachytherapy plays an important role in managing patients with advanced-stage tumors, improving the four-year survival rate to 46% for stage IIIB disease, compared to only 19% for tumors treated with external beam radiation alone 3 . This form of therapy allows high doses of radiation to be beamed directly at the tumor, while neighboring tissues receive lower radiation doses.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Brachytherapy for stage IIIB squamous cell carcinoma of the uterine cervix: survival and toxicity

Zuliani¹,

Cunha²,

Esteves³

2010

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

SummaryObjective. To compare survival and toxicity of three different treatments for stage IIIB cervix cancer: low-dose-rate (LDR), high-dose-rate (HDR) brachytherapy and association of HDR and chemotherapy. MethOds. Between 1985 and 2005, 230 patients with FIGO stage IIIB squamous cell carcinoma of the uterine cervix received 4-field pelvic teletherapy at doses between 40 and 50.4 Gy, with a different complementation in each group. The LDRB group, with 42 patients, received one or two insertions of LDR, with Cesium-137, in a total dose of 80 to 100Gy at point A. The HDR group, 155 patients received HDR in 4 weekly 7 Gy fractions and 9 Gy to 14.4 Gy applied to the involved parametria. The CHT group, 33 patients, were given the same treatment as the HDR group and received 5 or 6 weekly cycles of cisplatin, 40 mg per m2. Results. The five-year progression-free survival (PFS) was 60% for the HDR group and 45% for the LDR group, and the two-year PFS for the CHT group was 65% (p = 0.02). The five-year Overall Survival (OS) was 65% for the HDR group and 49% for the LDR group. The two-year OS was 86% for the CHT group (p = 0.02). Rectum toxicity grade II was 7% for the LDR group, 4% for the HDR group and 7% for the CHT group that had one case of rectum toxicity grade IV. cOnclusiOn. Patients that received HDR had better OS and PFS. The Chemotherapy-HDR association showed no benefit when compared to HDR only. Toxicity rates showed no difference between the three groups.

show abstract

“…The skepticism concerning HDR is based mainly on the risks for late complications. The data is too limited and the followup times too short to resolve the issue (47)(48)(49)(50)(51)(52)(53)(54)(55)(56)(57)(58)(59) …”

Section: Low Dose Rate Versus High Dose Ratementioning

confidence: 99%

Cervical Cancer (Cervix Uteri)

Einhorn¹

1996

Acta Oncologica

View full text Add to dashboard Cite

Summary and ConclusionsThis synthesis of the literature on radiotherapy for cervical cancer (cervix uteri) is based on 59 scientific articles, including 8 randomized studies, 1 prospective study, and 36 retrospective studies. These studies involve 34 024 patients.-Due to favorable anatomy and exceptionally good radiation tolerance of nearby pelvic organs, particularly the uterus, radiotherapy has become the dominant treatment method for cervical cancer.~ Surgery alone is used at the earliest stages where small tumor volumes are involved.-Further pathological findings, where cancer is more extensive than expected preoperatively, or when lymph node metastases are discovered, motivate postoperative radiotherapy even at early stages.-There is general agreement that advanced cervical cancer should be treated by radiotherapy alone. Clinical trials are under way that combine radiotherapy and chemotherapy, and even surgery. ~Two different methods of intracavitary brachytherapy are currently in use, low-dose rate therapy and highdose rate therapy. High-dose rate therapy appears to be economically more favorable. The possibility of higher risks for later complications associated with high-dosc rate therapy has not been fully studied.

show abstract

Treatment of carcinoma of the uterine cervix by remotely controlled afterloading intracavitary radiotherapy with high-dose rate: A comparative study with a low-dose rate system

Cited by 152 publications

References 2 publications

Results of concomitant chemoradiation for cervical cancer using high dose rate intracavitary brachytherapy: Study of JROSG (Japan Radiation Oncology Study Group)

Results of concomitant chemoradiation for cervical cancer using high dose rate intracavitary brachytherapy: Study of JROSG (Japan Radiation Oncology Study Group)

Brachytherapy for stage IIIB squamous cell carcinoma of the uterine cervix: survival and toxicity

Cervical Cancer (Cervix Uteri)

Contact Info

Product

Resources

About